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switched from clopidogrel to a Gen 2 APT, there was not an increased risk of stent
thrombosis. This data suggests that Gen 2 APT may be employed in higher risk
patients but do not increase the risk of stent thrombosis, implying adequate compli-
ance in these high-risk patients.
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Comparing the Procedural and 30-Day Outcomes in Patients with or without a History
of Coronary Artery Bypass Graft When Treating De Novo, Severely Calcified Coronary
Lesions with Orbital Atherectomy: Results from ORBIT II
Jeffrey W. Chambers,1 Michael S. Lee,2 Arthur C. Lee3
1Metropolitan Heart and Vascular Institute, Coon Rapids, MN; 2UCLA Medical Center,
Los Angeles, CA; 3The Cardiac and Vascular Institute, Gainesville, FL
Background: In prior studies, patients with previous coronary artery bypass grafting
(CABG) experienced signiﬁcantly greater incidence of adverse clinical events upon
subsequent repeat CABG, percutaneous coronary intervention, or medical treatment,
compared to patients with no prior CABG. In this analysis, we evaluate the procedural and
30-day outcomes in patients with and without a history of previous CABG in the ORBIT
II Trial.
Methods: The ORBIT II Trial, a prospective, multicenter, non-blinded clinical trial
that enrolled 443 consecutive patients, was designed to evaluate the safety and efﬁcacy
of the coronary Orbital Atherectomy System to prepare de novo, severely calciﬁed
coronary lesions for stent placement. Procedural and 30-day outcomes in patients with
history of previous CABG (N¼65) and no history of CABG (N¼378) were evaluated
in this analysis.
Results: Compared to patients without history of previous CABG, patients with
history of CABG were more likely to be male (p¼0.005) and have a higher prevalence
of diabetes mellitus (p¼0.025), history of dyslipidemia (p¼0.008), hypertension
(p¼0.028), and myocardial infarction (MI) (p<0.0001). The rate of procedural success
(stent delivery with residual stenosis <50% without the occurrence of an in-hospital
major adverse cardiac event (MACE)) was similar 83.1% (previous CABG) and 89.9%
(without previous CABG) (p¼0.132). Statistically similar low rates of severe dissection
(7.7% vs. 2.6%: p¼0.054), perforation (0% vs. 2.1%: p¼0.611), persistent slow ﬂow
(0% vs. 1.1%: p¼1.0), and abrupt closure (3.1% vs. 1.6%: p¼0.333) were observed in
the history of CABG and no history of CABG groups, respectively. As estimated by
Kaplan Meier at 30-days, patients had similar low rates of MACE (previous CABG:
16.9% vs. without previous CABG: 9.3%, p¼0.070).
Conclusion: Preparation of severely calciﬁed coronary lesions with the coronary
Orbital Atherectomy System facilitated stent delivery in patients with a history of
previous CABG, resulting in low rates of 30-day MACE.CRT-129
Outcomes in Chronic Kidney Disease Patients Treated for Coronary Arterial Disease
Utilizing the Orbital Atherectomy System: An ORBIT II Sub-Analysis
Arthur C. Lee,1 Stevan I. Himmelstein,2 Jeffrey W. Chambers3
1The Cardiac and Vascular Institute, Gainesville, FL; 2The Stern Cardiovascular Center,
Memphis, TN; 3MetropolitanHeart and Vascular Institute,MercyHospital, CoonRapids,MN
Background: Cardiovascular disease is common in patients with chronic kidney
disease (CKD) and often results in severely calciﬁed lesions that are difﬁcult to cross
and treat. As a result, this population may have worse clinical outcomes following
percutaneous coronary intervention compared to patients without CKD. Clinical trials
typically exclude this patient population.
Methods: ORBIT II patients with severely calciﬁed coronary lesions treated with the
coronary Orbital Atherectomy System (OAS) were divided into three groups based on
the estimated glomerular ﬁltration rate (eGFR, mL/min/1.73m2) at baseline: I (CKD
Stages 3-5), eGFR<60 (n¼115); II (CKD stages 1-2), eGFR 60 to <90 (n¼218);
and III (normal), eGFR90 (n¼108).
Results: Patients in groups I and II were older (p<0.0001), and there were more
females in these two groups than in group III (p¼0.0468). History of previous stroke
(p¼0.0351) was more prevalent in groups I and II. In addition, the total length of
calcium was signiﬁcantly longer in group II (p¼0.0003). Similar successful stent de-
livery occurred in 97.4%, 97.2% and 99.1% (p¼0.7006) of cases with <50% residual
stenosis in 99.1%, 98.2% and 99.1% (p¼0.8779) of subjects in groups I, II and III,
respectively. Statistically similar low rates of severe dissection (1.7%, 5.5%, 0.9%:
p¼0.0709), perforation (2.6%, 1.8%, 0.9%: p¼0.7343), persistent slow ﬂow (0.9%,
1.4%, 0.0%: p¼0.8110), and abrupt closure (1.7%, 1.8%, 1.9%: p¼1.0000) were
observed in groups I, II, and III, respectively. The 30 day Freedom from MACE rates
in groups I (87.8%), II (87.1%), and III (96.3%) were similar (p¼0.0555).
Conclusion: Severely calciﬁed coronary lesion pre-treatment with the coronary OAS
resulted in similar 30 day Freedom from MACE rates and low rates of procedural
complications in CKD patients compared with the non-CKD patients despite the
older demographic and longer length of calcium in the CKD patients.
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Gender Difference on Procedural and 30-day Outcomes in Patients Treated with
Orbital Atherectomy for De-Novo, Severely Calcified Coronary Lesions: Results from the
ORBIT II Trial
Christopher Kim,1 Jeffrey W. Chambers2
1Utah Cardiology, PC, Layton, UT; 2Metropolitan Heart and Vascular Institute, Mercy
Hospital, Coon Rapids, MN
Background: Previous studies have shown a negative correlation between female
gender and adverse events after percutaneous coronary intervention (PCI). In this
analysis, we evaluate the procedural and 30-day outcomes of male and female patients
in the ORBIT II Trial.
Methods: The ORBIT II Trial, a prospective, multicenter, non-blinded clinical
trial that enrolled 443 consecutive patients, was designed to evaluate the safety and
efﬁcacy of the coronary Orbital Atherectomy System to prepare de novo, severely
calciﬁed coronary lesions for stent placement. Procedural and 30-day outcomes in
male patients (N¼286) were compared to female patients (N¼157). The primary
safety endpoint was freedom from major adverse cardiac events (MACE) at 30 days
post-procedure. The primary efﬁcacy endpoint was procedural success deﬁned as
stent delivery with a residual stenosis of <50% without the occurrence of an in-
hospital MACE.
Results: Compared to males, females were older (p¼0.0011) and had lower eGFR at
baseline (p¼0.0024). However males had a higher rate of previous coronary artery
bypass graft (p¼0.0048). Both males and females met the primary safety endpoint
goal of 83% (89.2% [95% CI: 85.5%-92.8%] vs. 90.4% [95% CI: 85.7%-95.2%]) and
primary efﬁcacy endpoint of 82% (88.4% [95% CI: 84.1%-91.9%] vs. 89.7% [95%
CI: 83.9%-94.0%]). As estimated by Kaplan Meier at 30-days, males and females
had similar low rates of MACE (10.8% vs. 9.6%, p¼0.6613), myocardial infarction
(MI) (10.1% vs. 8.9%, p¼0.666), target vessel revascularization/target lesion
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0.7%, p¼0.9976).
Conclusion: This sub-analysis of the ORBIT II study demonstrates that males and
females treated with orbital atherectomy for severely calciﬁed coronary arteries
(generally regarded as high-risk revascularization) demonstrate similar 30-day out-
comes. In the context of the larger study, one can presume that the novel coronary
Orbital Atherectomy System is a safe and effective adjunctive therapy for severely
calciﬁed coronary lesions in both men and women.C
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Feasibility of the Use of the Tryton™ Dedicated Bifurcation Stent via the Transradial
Route - A Single Centre Experience
Ashish Shah, Muezz Uddin, Shantu Bundhoo, Richard Anderson, Tim Kinnaird
University Hospital of Wales, Cardiff, Cardiff, United Kingdom
Background: The use of the Transradial access (TR) for the treatment of Coronary
Bifurcation Lesions (CBL) with Percutaneous Coronary Intervention (PCI) can be
limited where a two stent strategy is required as larger sheath and guide catheters are
required to facilitate stent delivery. With the development of newer dedicated bifur-
cation stents, there is an increasing trend of these stents to be adopted in PCI centres
to treat CBL’s. We report our experience of the use of the Tryton dedicated side
branch bifurcation stent at our default TR centre where 90% of all PCI are carried out
via the TR.
Methods: This was a prospective study of all patients who were found suitable to
undergo PCI to CBL’s using the Tryton stent between September 2009 and June
2013. Data on patient demographics and procedure characteristics was collected from
the local hospital database.
Results: 36 patients (Male 69.4%, age 68.1 years) underwent PCI using the
19mm long Tryton bifurcation stent. Most of the CBL’s treated were located in
the LAD/Branch (52.8%), followed by the Circumﬂex/Branch (27.8%), Left
main stem/Branch (13.9%), RCA/Branch (2.7%) and LIMA graft (2.7%).
Tryton stents dimensions (Side branch/Main branch diameters) deployed were
(2.5/2.5mm - 11.1%; 2.5/3.0mm - 25%; 2.5/3.5mm - 47.2%; 3.0/3.5mm - 8.3%
and 3.5/4.0mm - 8.3%). 91.6% of cases were carried out via 6F guide catheters
with the remaining cases carried out via the 7F. Mean contrast volume, radiation
dose and ﬂuoroscopy times were 306 mls, 98.8 Gy/cm2 and 28.2 minutes
respectively. 94.4% of all cases were successfully carried out via the TR route with
remaining cases switching to the transfemoral route to successfully complete the
procedure.
Conclusions: When treating CBL’s, a wide range of Tryton dedicated side branch
stents can be safely and effectively deployed via the TR route using 6F/7F Guide
catheter systems. This can avoid the use of the transfemoral route and its associated
potential vascular complications.CABG
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Under-Utilization of Statins and Aspirin Following Coronary Artery Bypass Graft
Surgery
Kevin Curl, Bryan LeBude, Nicholas Ruggiero, David Fischman, Andrew Rose,
Sulay Patel, David Ogilby, Paul Walinsky, Babu Jasti, Michael Savage
Thomas Jefferson University Hospital, Philadelphia, PA
Background: Coronary artery bypass graft (CABG) surgery is commonly performed
to treat ischemic heart disease, but long term beneﬁts are limited by patency of
saphenous vein grafts. Both statin medications and aspirin hold class I indications for
all post-CABG patients and should be continued indeﬁnitely unless contraindication
exists. Unfortunately, there is limited data regarding long-term usage of these medi-
cations. We assessed utilization rates among post-CABG patients without docu-
mented contraindication.
Methods: A retrospective analysis of post-CABG patients presenting to the Thomas
Jefferson University cardiac catheterization laboratory for a catheterization procedure at
least 3 years after surgery was performed. Inpatient and outpatient records were
reviewed to assess prescribing patterns of these medications, as well as other pertinent
clinical and laboratory data.
Results: The study population consisted of 381 consecutive patients who presented
on average 11  6 years from the time of CABG. Mean age of our study population
was 69  11 years with 78% male. The most common indications for catheterization
were unstable angina (36%), non-STEMI (22%), and an abnormal stress test (15%).
Only 67% of patients were being prescribed a statin, while 75% were prescribed
aspirin. Only 52% were prescribed both at the time of catheterization. Three percent
had a documented intolerance to statin therapy. Patients prescribed a statin had a
signiﬁcantly lower mean LDL (87 vs. 106 [p<0.01]) and total cholesterol values (151
vs. 162 [p<0.01]). Thirty ﬁve percent of patients had LDL  100. Only 43% of
saphenous vein grafts among the patients not on statin medications remained patent
an average of 11 years post-CABG surgery.
Conclusions: Long-term statin and aspirin use following CABG surgery remains
suboptimal despite clear guideline recommendations and clinical trial evidence of their
effectiveness. Coordinated efforts are needed to improve long-term medication usage
in this subset of high risk patients.
Cardiovascular Pharmacology
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Omeprazole Use is Associated with Increased Cardiovascular Complications in Asian
Patients on Aspirin and Clopidogrel After Percutaneous Coronary Intervention
Min Sen Yew, Poh Shuan Daniel Yeo, Jau Lueng Paul Ong, Lijuan Mira Shen,
Hee Hwa Ho, Fahim Haider Jafary, Yau Wei Ooi, Kwok Kong Jason Loh,
Ko Beng Julian Tan, Chee Guan David Foo
Tan Tock Seng Hospital, Singapore, Singapore
Background: Dual anti-platelet therapy (DAPT) with Aspirin and a Thienopyridine-
derivative P2Y12 Inhibitor (commonly Clopidogrel) is mandatory after Percutaneous
Coronary Intervention (PCI). H2 receptor antagonists (H2RA) or Proton Pump
Inhibitors (PPI) are prescribed to reduce gastrointestinal bleeding risk.
